Vaxxinity

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; anti-PCSK9 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Dallas, Texas.

Our mission is to provide innovative, safe, and effective therapeutics that bring hope to those living with infectious, immune and allergic diseases.

Our vision is to be the global leader in developing and delivering cutting-edge immunotherapeutics that change the lives of people around the world.

Vaxxinity has been an award winner for its innovative therapies and research activities. The company has won several awards, including the Wall Street Journal's Top Biotechnology Companies of 2018 and the Business and Financial World's Breakthrough Health & Technology Company of the Year award in 2019.